TG Therapeutics (TGTX) reported second-quarter 2026 total global revenue of $240.3 million and net income of $7.8 million, with diluted earnings per share of $0.05. Product revenue rose to $235.8 million for the quarter, including $227.7 million in BRIUMVI U.S. net product revenue.
The company raised its full-year 2026 total global revenue target to approximately $950 million and lifted its BRIUMVI U.S. net product revenue target to approximately $890 million to $905 million.
- Second-quarter total revenue was $240.3 million, compared with $141.1 million a year earlier.
- Net income was $7.8 million, compared with $28.2 million in the second quarter of 2025.
- BRIUMVI U.S. net product revenue was $227.7 million, up approximately 64% from the year-ago period.
- Cash, cash equivalents and investment securities were $612.3 million as of June 30, 2026.
- TG Therapeutics announced positive Phase 3 ENHANCE results and expects top-line Phase 3 data for subcutaneous BRIUMVI at year-end 2026 or in early 2027.
$TGTX Hedge Fund Activity
We have seen 203 institutional investors add shares of $TGTX stock to their portfolio, and 144 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANE STREET GROUP, LLC added 1,071,694 shares (+110.5%) to their portfolio in Q1 2026, for an estimated $35,601,674
- CITADEL ADVISORS LLC added 911,852 shares (+90.2%) to their portfolio in Q1 2026, for an estimated $30,291,723
- SOLEUS CAPITAL MANAGEMENT, L.P. added 890,007 shares (+28.4%) to their portfolio in Q1 2026, for an estimated $29,566,032
- EVENTIDE ASSET MANAGEMENT, LLC removed 716,414 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $23,799,273
- WOODLINE PARTNERS LP added 715,500 shares (+inf%) to their portfolio in Q1 2026, for an estimated $23,768,910
- DIMENSIONAL FUND ADVISORS LP added 612,068 shares (+129.5%) to their portfolio in Q1 2026, for an estimated $20,332,898
- BANK OF AMERICA CORP /DE/ added 610,195 shares (+71.7%) to their portfolio in Q1 2026, for an estimated $20,270,677
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
